Reference:
Kennedy, R. F., & Nass, M. (2021). Concerns over COVID-19 vaccination for children aged 5-11. Retrieved from Children’s Health Defense.
Summary:
In a letter to the FDA and VRBPAC members, Children’s Health Defense (CHD) expressed strong opposition to the potential Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for children aged 5-11. The authors, Robert F. Kennedy Jr. and Dr. Meryl Nass, outlined multiple concerns, arguing that the risks associated with the vaccine outweigh its benefits due to the low incidence of severe COVID-19 outcomes in this age group. They highlighted that many children possess natural immunity and that the clinical trials were insufficient to ensure safety. Moreover, they raised ethical concerns regarding coercive vaccination practices and the potential for severe adverse effects, including myocarditis. The letter cautioned that authorising the vaccine would violate medical ethics and could expose children to unnecessary risks. CHD signalled its intention to pursue legal action if the vaccine was approved, urging the committee to reconsider the implications of their decisions on children’s health.